Stock listing

Munich:YPH Astellas Pharma Inc. Aktie

German listing (Munich) of Astellas Pharma Inc. · home listing Tokyo:4503

Follow Astellas Pharma Inc. into a list and get an email when it puts out news.

Share price · MUN:YPH

€14.44 EUR +0.33 (+2.3%)

Close on Oct 27, 2026

Day range
€14.44 – €14.44 EUROct 27, 2026
Market cap
€27.47B EURAt the close on Oct 27, 2026 · price × 1.90B shares outstanding
Astellas Pharma Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
OTC:ALPMY$15.94 USD+0.02 (+0.1%)5,503$16.17$16.17$15.94$15.92Close on Oct 27, 2026
OTC:ALPMF$16.94 USD+0.19 (+1.1%)700$16.03$17.50$16.03$16.75Close on Oct 27, 2026
Frankfurt:YPH€12.70 EUR-1.40 (-9.9%)30€14.30€14.70€12.70€14.10Close on Oct 30, 2026
Dusseldorf:YPH€13.90 EUR-0.10 (-0.7%)—€14.20€14.30€13.90€14.00Close on Oct 30, 2026
Munich:YPH€14.44 EUR+0.33 (+2.3%)—€14.44€14.44€14.44€14.11Close on Oct 27, 2026
Frankfurt:YPHA€14.30 EUR+0.20 (+1.4%)—€14.30€14.30€14.30€14.10Close on Oct 30, 2026
Ticker
Munich:YPH
Asset type
Stock
Sector
Health care
Industry
Pharmaceuticals
Exchange
Munich
Currency
EUR

What changed lately

Calls

Replays

  • Astellas Pharma (Tokyo:4503) Q4 2025 Earnings Call

    Mon, Apr 27, 2026 · 2:30 AM ET

    Watch Transcript

  • Astellas Pharma (Tokyo:4503) Q3 2025 Earnings Call

    Fri, Feb 06, 2026 · 2:00 AM ET

    Watch Transcript

  • Astellas Pharma (Tokyo:4503) Q2 2025 Earnings Call

    Thu, Oct 30, 2025 · 2:30 AM ET

    Watch Transcript

Latest news

Astellas Highlights Data Advancing Cancer Care and Innovation for Patients with Hard-to-Treat Cancers at ESMO 2026

Oct 6, 2026

Astellas Doses First Patient in Phase 3 Study of setidegrasib in Previously Treated KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer

Sep 23, 2026

Enhertu® Plus Pertuzumab Approved in the EU as First New Regimen in More than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer

Sep 1, 2026

Astellas enters voluntary agreement with U.S. government supporting affordable access to medicines

Aug 31, 2026

Astellas Doses First Patient in Phase 3 Study of ASP2138 in CLDN18.2-postive and HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma

Aug 24, 2026

Financial Results (Q1 YTD/FY2026)

Aug 5, 2026

U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

Jul 10, 2026

Astellas Announces Five-Year Corporate Strategic Plan to Deliver Greater VALUE Faster for Patients and Position Itself as a Sustainable Growth Company

May 26, 2026

Astellas to Present Data on Long-Term Outcomes and Clinical Use of Its Portfolio Across Disease Stages at ASCO 2026

May 18, 2026

Japan Regenerative Medicine Market Trends and Forecasts to 2035 Featuring Astellas Pharma, Fujifilm, JCR Pharmaceuticals, Sumitomo Pharma, Takeda, and Terumo

May 13, 2026

All Astellas Pharma Inc. news

Decks

Astellas Pharma Inc. on 6ix

Sector
Health care
Industry
Pharmaceuticals
News releases
25 in the last 12 months · 49 in all · newest Oct 6, 2026 · oldest 2024
Calls
11 calls with a replay · 11 with a transcript · latest Apr 27, 2026
Decks
118 decks · latest Aug 5, 2026

Where Astellas Pharma Inc. is listed

ListingExchangeCountryCurrency
Tokyo:4503 アステラス製薬 · Home listingTokyoJapanJPY
OTC:ALPMYOTCUnited StatesUSD
OTC:ALPMFOTCUnited StatesUSD
gettex:YPHgettexGermanyEUR
Tradegate:YPHTradegateGermanyEUR
LS Exchange:856273LS ExchangeGermanyEUR
Frankfurt:YPHFrankfurtGermanyEUR
Lang & Schwarz:856273Lang & SchwarzGermanyEUR
BMV:4503NBMVMexicoMXN
Stuttgart:YPHStuttgartGermanyEUR
Dusseldorf:YPHDusseldorfGermanyEUR
BIVA:4503NBIVAMexicoMXN
Munich:YPH · This pageMunichGermanyEUR
Hamburg:YPHHamburgGermanyEUR
Frankfurt:YPHAFrankfurtGermanyEUR
Hanover:YPHHanoverGermanyEUR

Log in to ask 6ix AI your own questions about Astellas Pharma Inc.